Behavioral Weight Loss Program Successful Among Survivors of Endometrial Cancer

Article

Endometrial cancer survivors experienced clinically significant weight loss after participating in a behavioral weight loss program.

Implementation of a behavioral weight loss (BWL) program resulted in clinically significant weight loss among survivors of endometrial cancer, although investigators note a need for longer follow up on additional psychosocial and behavioral outcomes, according to a study published in Gynecologic Oncology Reports.

Over a 12-month period, patients who participated in the program were able to complete 28.3 ± 14.1 appointments, which induced an average weight change of –14.2 ± 7.8 kg (–13.3 ± 7.4%) at 6 months and –16.4 ± 12.5 kg (–15.3 ± 11.4%) at 12 months (P <.001). Moreover, at 12 months, patients in the control group had an average weight change of −1.7 ± 8.4 kg (−2.3 ± 7.6%; P <.001). In the BWL cohort, the change in mean body mass index (BMI) at 6 months was –4.8 ± 4.5 (P <.001); at 12 months, the change in BMI in the BWL and control groups were –5.2 ± 5.9 (P <.001) vs –0.9 ± 3.2 (P = 0.007), respectively.

In the nonrandomized experimental trial, investigators set out to assess whether enrollment in a BWL program would be more effective in facilitating clinical weight loss among endometrial cancer survivors with obesity compared with a matched control group. Primary outcomes for the trial included weight loss at 12 months and BMI change at 12 months.

Patients were screened for eligibility from March 2019 to January 2020. Eligibility criteria included being 18 years or older, having an endometrioid endometrial cancer diagnosis, and having no known metastatic disease. Patients were also required to have completed all endometrial cancer treatments 2 months prior to study enrollment and needed to have a BMI of 30 or higher.

According to investigators, “Profile by Sanford is a personalized weight loss and weight-loss maintenance program that utilizes a one-on-one lifestyle behavior coaching program focused on healthy diet and physical activity. Program membership includes health coaching, a Wi-Fi Smart scale that syncs with an interactive web platform and coaching application, along with a nutrition plan.”

Patients enrolled on the 12-month study after being recruited following a standard follow-up oncology visit. They were then contacted by a Profile health coach who scheduled an initial 1-hour session to assess experiences, motivation, and health and lifestyle. All subsequent appointments were weekly and lasted 30 minutes. Health coaches also helped survivors with customized meal planning and found safe ways to increase daily activity levels.

The control group was pulled from Sanford’s cancer registry and were matched based on age, BMI, disease type, FIGO stage, and treatment dates. Those in the control group continued with standard care clinic visits and underwent tests and procedures based on physician recommendation.

A total of 25 patients enrolled on the study and were put in the intervention arm—3 of whom withdrew—vs 28 patients in the matched control arm. In the intervention arm, the average enrollment took place 19.0 ± 17.4 months from their last treatment.

Reference

Bell M, Reed V, Wernisch J, et al. Effectiveness of profile by Sanford behavioral weight loss program for weight loss following endometrial cancer treatment. Published online November 26, 2021. doi:10.1016/j.gore.2021.100897

Recent Videos
Ritu Salani, MD, discussed investigational endometrial cancer treatment options for patients with varying subtypes of endometrial cancer.
The second interim analysis of the phase 3 RUBY trial found the safety profile was consistent with the first interim analysis and no new deaths due to AEs were observed.
The phase 3 RUBY trial evaluated dostarlimab in combination with carboplatin/paclitaxel in patients with primary advanced or recurrent endometrial cancer.
Although immature, overall survival data from the KEYNOTE-868 trial may support the use of pembrolizumab plus chemotherapy in patients with endometrial cancer.
Dostarlimab plus chemotherapy appears to yield favorable overall survival in patients with mismatch repair proficient endometrial cancer.
Pembrolizumab combined with carboplatin and paclitaxel resulted in response rates in patients with recurrent endometrial cancer.
Future analyses will look at durvalumab/olaparib for endometrial cancer populations with TP53 and POLE alterations, as well as those with estrogen receptor and progesterone receptor positivity.
Patients with mismatch repair proficient, newly diagnosed, advanced or recurrent endometrial cancer may have enhanced benefit with the addition of olaparib to durvalumab.
Dostarlimab plus chemotherapy produces notable benefits among patients with advanced, mismatch repair deficient endometrial cancer in the phase 3 RUBY trial.
Related Content